Bachmann Nicolas, Loebner Hannes A, Althaus Alexander, Hemmatazad Hossein
Department of Radiation Oncology, Inselspital, Bern University Hospital, University of Bern, Bern, CHE.
Cureus. 2025 Apr 14;17(4):e82239. doi: 10.7759/cureus.82239. eCollection 2025 Apr.
Due to respiratory motion, treating sternal metastases with stereotactic body radiotherapy (SBRT) is challenging, often requiring large irradiation volumes to account for target movement. To address this, we implemented a straightforward approach by placing skin fiducial markers near the sternal metastasis, enabling real-time motion synchronization with the CyberKnife® System (Accuray Inc., Sunnyvale, CA). Advances in anti-cancer therapies have significantly extended survival in metastatic patients, increasing their likelihood of requiring re-irradiation and experiencing late toxicities. We present the outcomes of two patients, one with metastatic hepatocellular carcinoma (mHCC) and one with metastatic breast cancer (mBC), who underwent two courses of SBRT for sternal metastases using the CyberKnife® and skin fiducial markers for motion management. Both patients tolerated the treatment well, achieving complete pain relief and durable local control. No late toxicity was observed in the mHCC case, while the mBC patient developed significant left anterior descending artery (LAD) stenosis, which may have been linked to cumulative radiation exposure. Given the known risk of cardiac toxicity associated with radiation therapy, these findings underscore the importance of minimizing cardiac dose to reduce long-term toxicity, particularly in re-irradiation cases.
由于呼吸运动,采用立体定向体部放疗(SBRT)治疗胸骨转移瘤具有挑战性,通常需要较大的照射体积来考虑靶区运动。为了解决这一问题,我们实施了一种简单的方法,即在胸骨转移瘤附近放置皮肤基准标记物,从而实现与射波刀系统(Accuray公司,加利福尼亚州桑尼维尔)的实时运动同步。抗癌治疗的进展显著延长了转移性患者的生存期,增加了他们需要再次放疗以及出现晚期毒性反应的可能性。我们介绍了两名患者的治疗结果,一名是转移性肝细胞癌(mHCC)患者,另一名是转移性乳腺癌(mBC)患者,他们均使用射波刀和皮肤基准标记物进行运动管理,针对胸骨转移瘤接受了两个疗程的SBRT。两名患者对治疗耐受性良好,疼痛完全缓解且实现了持久的局部控制。mHCC病例未观察到晚期毒性反应,而mBC患者出现了严重的左前降支(LAD)狭窄,这可能与累积辐射暴露有关。鉴于放疗已知存在心脏毒性风险,这些发现强调了将心脏剂量降至最低以减少长期毒性的重要性,尤其是在再次放疗的病例中。